{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:29:42Z","timestamp":1787923782685,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107373","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:24:37Z","timestamp":1783178677000},"page":"107373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis"],"prefix":"10.1016","volume":"113","author":[{"given":"Katarina","family":"Te\u0161ija","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0161an","family":"Sredanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Gabeli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Barun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Krbot Skori\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107373_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107373_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with Rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.msard.2026.107373_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with Rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.msard.2026.107373_bib0004","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-026-13960-5","article-title":"Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study","volume":"273","author":"Bove","year":"2026","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107373_bib0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","article-title":"Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis","volume":"272","author":"Davies","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107373_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107373_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241277736","article-title":"Bar-or A. long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials","volume":"17","author":"Derfuss","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107373_bib0008","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go?","volume":"39","author":"Furst","year":"2009","journal-title":"Semin. Arthritis. Rheum."},{"key":"10.1016\/j.msard.2026.107373_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16331","article-title":"Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study","volume":"31","author":"Hallberg","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107373_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16331","article-title":"Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study","volume":"31","author":"Hallberg","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107373_bib0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107373_bib0012","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107373_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104712","article-title":"Low and high serum IgG associates with respiratory infections in a young and working age population","volume":"94","author":"Holma","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2026.107373_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105776","article-title":"Ocrelizumab in people with primary progressive multiple sclerosis: a real-world multicentric study","volume":"89","author":"Krbot Skori\u0107","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107373_bib0015","article-title":"Real-world safety and effectiveness of ofatumumab in multiple sclerosis: a clinic-based study in Australia","volume":"12","author":"Montague","year":"2026","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107373_bib0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1177\/13524585251412125","article-title":"Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: the REPLACE-MS study","volume":"32","author":"Sangha","year":"2026","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107373_bib0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2026.107373_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1738865","article-title":"Real-world comparison of anti-CD20 therapies: efficacy, infections, and immune profiles in a German cohort","volume":"17","author":"St\u00f6gbauer","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2026.107373_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2026.106994","article-title":"Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: a multicenter cohort study","volume":"107","author":"Te\u0161ija","year":"2026","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107373_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clicom.2023.07.003","article-title":"Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: a population-based cohort study","volume":"4","author":"Vanoverschelde","year":"2023","journal-title":"Clin. Immunol. Commun."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:50:36Z","timestamp":1787921436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":20,"alternative-id":["S2211034826004098"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107373","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107373"}}